Nearly every patient who received an investigational vaccine designed to train the immune system to find and kill lingering or recurring pancreatic cancer cells developed an immune response against the targeted mutations in a recent clinical trial.
The University of Colorado Anschutz took part in the phase 2 trial that included 24 clinical sites across the country.
Unlike traditional vaccines meant to prevent disease, the vaccine called camupepimut and developed by Elicio Therapeutics is designed to delay or prevent recurrence of the nation’s third deadliest cancer (behind lung and colorectal).
Although the primary goal of the trial to establish association with longer-term survival was unmet, the results were positive enough to progress to the next phase. The findings were published last month in Nature Medicine.
“In the trial, 99% of patients mounted an immune response, developing an increased T-cell response to at least one of the targets, which is encouraging,” said Alexis Leal, MD, assistant professor of medicine in the Division of Medical Oncology and the Gina Guy Endowed Chair in Pancreatic Cancer Research at the University of Colorado Anschutz.
“It doesn't necessarily translate to disease-free survival, but it shows that the vaccine is doing what it should.”
As far as increasing survival time before recurrence, numerically, the vaccine arm appeared to be better – 23.8 months in those who received the vaccine versus 21.2 months in those in the observation arm – but it was not statistically significant, Leal said.
Leal and colleagues at the CU Anschutz Cancer Center took part in both phase 1 and 2 of the AMPLIFY-7P trial co-led by the Mayo Clinic and Memorial Sloan Kettering cancer centers.
Did you know?
The pancreas is a pear-sized gland in the back of the abdomen that helps with digestion and blood sugar control.
With subtle warning signs and no screening test, cancer of the pancreas is often advanced when it’s discovered. That, and high recurrence rates, lead to poor five-year survival statistics, particularly if the cancer has spread.
“This is a cancer that has a high propensity for recurrence, has a tendency to spread early and, unfortunately, doesn't have a screening test that's approved,” Leal said.
Despite having world-class surgeons, advanced chemotherapy protocols and a higher survival rate than the national average, pancreatic cancer still challenges Leal and her colleagues at the CU Anschutz Cancer Center, recognized for excellence in pancreatic cancer care.
“So not uncommonly when we find these, they tend to be more advanced,” Leal said. “The only way to cure these cancers is with a combination of surgery and chemotherapy, but unfortunately, even with that, a large proportion of patients develop cancer recurrence.”
The study involved 144 participants with stage 1-3 KRAS-mutated pancreas adenocarcinoma (PDAC), which accounts for over 90% of all pancreatic cancers. Patients must have undergone surgery, completed chemotherapy and shown no detectable sign of disease to qualify for the trial.
“KRAS is a gene that's frequently mutated in certain cancers, and when mutated, it leads to uncontrolled cell growth and division,” Leal said. “In pancreas cancer, 90 to 95% of them harbor a KRAS mutation. The mutated KRAS essentially allows the cancer to constantly be dividing and making cancer cells,” Leal said.
The vaccine targeted seven KRAS mutations.
“What this cancer vaccine is seeking to do is to teach the immune system to see these mutant KRAS cells in the hopes that if there are cancer cells that have survived surgery and chemotherapy, the immune cells can find and kill them.”
Unlike the personalized mRNA cancer vaccines generating excitement in the field, including one in clinical trials for pancreas cancer, camupepimut is an “off-the-shelf” vaccine.
“It means that it doesn't need to be individualized for a patient,” Leal said. “So as long as you have had pancreas adenocarcinoma and you carry one of those seven mutations that are targeted by the vaccine – which, that testing is very easy to do – you may be eligible for that vaccine,” she said.
The chief benefits of off-the-shelf vaccines are broader access and lower production costs.
With mRNA vaccines, tissue from a patient’s tumor is collected, preserved and used in the lab to essentially make a DNA profile for the tumor to design a vaccine that targets that individual tumor, Leal said.
“So it’s more involved. It's not just ready and waiting to be able to be used. It'll be interesting to see how these (camupepimut vaccines) compare.”
Camupepimut was developed to target the lymph nodes to amplify the immune response generated by the vaccine. It’s given in four shots, one in each arm and one in each leg.
“In the arms, the next stop is the lymph nodes of the underarm, and in the legs, the lymph nodes in the inguinal region, where your leg meets your pelvis. Delivering a vaccine in this way gets each of these lymph node areas engaged and dramatically increases the immune response,” Leal said.
Warning signs of pancreatic cancer
- Pain in the back or stomach
- Bloating or abdominal swelling
- Trouble digesting food (leading to nausea, indigestion and loss of appetite)
- Unexplained weight loss
- Yellowing of skin or eyes (jaundice)
- Changes in bowel movements
- New or changing diabetes
During subgroup analyses, researchers found that patients with no detectable circulating tumor DNA (genetic material shed by cancer cells into the bloodstream), tended to do better in both treatment arms – the vaccine arm with 96 patients and standard treatment arm (observation) with 48 patients.
“For those in the vaccine arm, 70% of them were alive without recurrence at 18 months, while 56% of them were alive in the observation arm at 18 months,” Leal said.
Patients who had undergone prior radiation had lower immune responses, and patients with stage 3 cancers also had poorer outcomes.
Researchers are expected to adjust for these findings and enroll a larger sample group for the phase 3 trial.
“The hope is that this vaccine will help to prevent recurrence, but this study didn't prove that yet,” Leal said. “These findings are encouraging, but a larger phase 3 trial is planned to see if we could confirm effectiveness.”
In her field, it’s all about time, a precious commodity that keeps her pushing for better answers, Leal said.
“My hope is always that I can help my patients achieve the best outcomes that they can, at whatever stage cancer that they have. Time is precious, and if treatments can provide another six months or year or longer, that is time that someone would not have had otherwise. Being able to help people get that additional time is incredibly fulfilling.”
How does the mKRAS vaccine work?
Alexis Leal, MD, explains how the experimental mKRAS vaccine for pancreas cancer works by comparing the body’s immune system to a police department. The vaccine shows the detectives or patrol officers (dendritic cells) a “wanted poster” (pieces of the mutant KRAS), so that they know what the bad guys look like.
Normally, the dendritic cells – responsible for surveilling the body for troublemakers (cancer cells, bacteria, etc.) – would travel back to police headquarters (the lymph nodes) after finding an invader to gather backup. But, with this vaccine, the cells travel directly to the lymph nodes to deliver the “wanted poster” and expand their forces for attack.
The captains (helper T cells) lead the operation and mobilize the SWAT team (killer T cells), which seeks out and destroys the mutant KRAS cells. When the mutant cells break apart, they disperse pieces of the cells that introduce more “clues” for the detectives to target, broadening the immune response.
Key points:
- An experimental pancreatic cancer vaccine triggered an immune response in 99% of trial participants.
- The vaccine targets seven KRAS mutations commonly associated with pancreatic cancer.
- The phase 2 trial involved 144 patients across 24 clinical sites, including CU Anschutz.
- The trial did not demonstrate a statistically significant improvement in recurrence-free survival.
- Researchers plan a larger phase 3 trial to investigate whether the vaccine can reduce cancer recurrence.